Anandas MRX epilepsy trials: Key insights with Jeremy Sturgess-Smith – ICYMI [Video]

Ananda Developments Plc (AQSE:ANA) finance director Jeremy Sturgess-Smith talked with Proactive about the company’s recent progress, highlighted in its interim results.

Specifically, he discussed Ananda’s advancements with its MRX1 and MRX2 formulations, emphasising the two ongoing UK-based phase III studies targeting drug-resistant epilepsy.

These studies, conducted by University College London and Great Ormond Street Hospital, are partially funded by the NHS, marking a significant collaboration that supports Ananda’s financial outlook.

Proactive: So the company is out with your interim results ending July 31st, 2024. Lots going on in that period, especially around your formulations, MRX1 and MRX2.

Jeremy Sturgess-Smith:Sure. We’ve had a momentous six and a bit months since the period started. The key event was the recent announcement about MRX2 and MRX2T—two patent-pending formulations. These are being used in two phase 3 studies here in the UK, conducted by University College London and Great Ormond Street Hospital, with funding from NHS England and the NIHR. …